Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print


Abstract:  
Purpose of the study
 Inflammatory processes in the brain play an important role in etiopathogenesis of Obsessive-Compulsive Disorder (OCD). Cyclooxygenase inhibitors such as celecoxib reduce the production of proinflammatory cytokines. This triple-blind study aimed to investigate the efficacy of the addition of Celecoxib to selective serotonin reuptake inhibitors in treating Obsessive–Compulsive Disorder (OCD)
Ther Methods
 Sixty patients who met the diagnostic and statistical manual of mental disorders criteria –fourth edition (DSM-IV) were recruited in the study for OCD screening by two psychiatrists to participate in the trial. The participants included 23 patients who received SSRIs and celecoxib (400 mg twice daily) and 22 patients in the control group that received SSRIs and placebo. At the beginning of the study, in weeks four, eight and 12, the patients were assessed by a psychiatrist using the Yale-Brown Obsessive Compulsive Scale (Y-BCOS).
The Results
 A significant difference was observed in the change of scores on the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) in week 12 compared  with the onset of the study in two groups (t:-8.976, df:38, P:0.001). There was a significant difference between two groups in obsession (F:49.19, df:1, P≤0.001) and compulsion (F:13.78, df:1, P:0.001),  and  in obsessive compulsive disorder (F:57.25, df:1, P≤0.001) which was higher in Celecoxib group.
The Conclusion
This study showed that adjuvant treatment with celecoxib can treat symptoms of OCD under treatment with SSRIs.


 
Type of Study: Original | Subject: Clinical Neuroscience
Received: 2019/08/19 | Accepted: 2020/07/25

Add your comments about this article : Your username or Email:
CAPTCHA

© 2020 All Rights Reserved | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb